Added to YB: 2025-06-10
Pitch date: 2025-06-07
REGN [bullish]
Regeneron Pharmaceuticals, Inc.
+49.27%
current return
Author Info
Notes From The Beauty Contest is a buy-side investor who thought it might be fun to write about stocks in their spare time and in their own way. Sign up for the newsletter.
Company Info
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Market Cap
$80.0B
Pitch Price
$496.62
Price Target
N/A
Dividend
0.45%
EV/EBITDA
14.60
P/E
18.76
EV/Sales
4.49
Sector
Biotechnology
Category
growth
Regeneron - Trials & Tribulations
REGN: Despite itepekimab COPD trial mixed results causing 18% stock drop, long-term outlook remains promising. One phase III trial met endpoint, company remains committed to program. Obesity pipeline strong with trevogrumab combo cutting muscle loss in half with semaglutide. 2027 catalyst: $800M annual Sanofi payment ends. Dupixent/Libtayo growing.
Read full article (5 min)